deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT02974855

PF-06741086 Multiple Dose Study in Severe Hemophilia

A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA

Sponsor: Pfizer

Conditions Hemophilia A or B
Interventions PF-06741086
Updated 22 times since 2017 Last updated: Nov 15, 2019 Started: Mar 8, 2017 Primary completion: Dec 3, 2018 Completion: Dec 3, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hemophilia A or B, this trial is completed. The trial is conducted by Pfizer and has accumulated 22 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Aug 2017 · 4 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Jan 2018 · 2 months · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Jan 2020 · 12 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2022 — Mar 2022 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE2

▶ Show 17 earlier versions

  1. Jan 2020 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jan 2019 — Jan 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  5. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  6. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  8. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE2

  10. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  11. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE2

  12. Nov 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  13. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  14. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  15. Apr 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE2

  17. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations